DGAP-News

MOLOGEN AG publishes nine month report for 2014: launch of pivotal study for the cancer immunotherapy MGN1703

DGAP-News: MOLOGEN AG / Key word(s): 9-month figures
MOLOGEN AG publishes nine month report for 2014: launch of pivotal
study for the cancer immunotherapy MGN1703

13.11.2014 / 07:00

---------------------------------------------------------------------

MOLOGEN AG publishes nine month report for 2014: launch of pivotal study
for the cancer immunotherapy MGN1703

- Start of patient enrolment for IMPALA (phase III) colorectal cancer
study

- New generation of immunomodulators introduced for the first time

- Financial situation remains stable

Berlin, 13 November 2014 - The biotechnology company MOLOGEN AG today
presented its nine month report for 2014. Considerable progress has been
made in the clinical development of the cancer immunotherapy MGN1703. This
included the launch of a randomized trial in the area of small cell lung
cancer as well as a phase III pivotal study in the field of colorectal
cancer. In addition, the company presented EnanDIM, a new generation of
immunomodulators, to the scientific community for the first time at the
beginning of October 2014. These advancements are reflected in the
increased expenses for research and development activities.

"We have reached a key milestone in the clinical development of our lead
product candidate MGN1703," comments Dr Matthias Schroff, CEO of MOLOGEN.
"In the third quarter, our company has started the treatment of first
patients in the IMPALA study, which is our pivotal study for colorectal
cancer."

The IMPALA study will include 540 patients from eight European countries.
The study is being conducted in cooperation with globally renowned oncology
experts as investigators.

Patient enrolment for the randomized IMPULSE study, which was launched at
the end of the first quarter, continues. The study is investigating the
efficacy of MGN1703 in the indication of small cell lung cancer.

EnanDIM: a new generation of immunomodulator
In October 2014, MOLOGEN presented preclinical data for the immunotherapy
EnanDIM for the first time. This new generation of active agent is expected
to trigger a broad immune activation while at the same time being well
tolerated. "We are filling our pipeline from the bottom up, and in doing so
we are demonstrating the innovative strength of our research and our good
position in the promising field of immunotherapy," explains Dr Schroff.

MGN1601, a therapeutic vaccine against renal cancer, is a further product
candidate in clinical development. In the third quarter, data from a